European Urology - Rebuttal from Authors re: Bertrand Guillonneau. To Demonstrate the Benefits of Laparoscopic Radical Prostatectomy? Eur Urol 2006;50:1160–1
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1161-1162 (December 2006)Article Outline: We would like to express our thanks for the helpful comments by Dr. Bertrand Guillonneau and agree with the general suggestions. However, some further detailed considerations need to be made.
read more
|
Prostate Biopsy and Optimization of Cancer Yield
Wednesday, 01 March 2006
It is hard to imagine practicing urology and urologic pathologic today without prostate-specific antigen (PSA) and multiple thin-bore needle biopsies, yet these advances only became available in the past 18 years. The old large-bore needles provided considerably more tissue for the pathologist to examine, but suffered from compression artifact on the edges and a small but significant risk of needle tracking of cancer; both problems are circumvented with the smaller-bore biopsy needles used today.
read more
|
Lack of Prophylactic Effect of Incadronate on Skeletal Lesions Associated with Implants of Prostate Cancer
Tuesday, 03 January 2006
Objectives: To evaluate prophylactic effects of bisphosphonate (BP) on skeletal lesions induced by prostate cancer (CaP).
read more
|
European Urology - The Actual Value of the Surgical Margin Status as a Predictor of Disease Progression in Men with Early Prostate Cancer
Thursday, 03 August 2006
Volume 50, Issue 2, Pages 258-265 (August 2006) 1. Introduction Radical prostatectomy has become a reliable means of curative treatment for men with early detected prostate cancer compared to no treatment [1], [2].
read more
|
European Urology - Nomograms and Medicine
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 884-886 (November 2006) Article Outline: Prostate cancer is the most common malignancy in European men.
read more
|
To Demonstrate the Benefits of Laparoscopic Radical Prostatectomy?
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1160-1161 (December 2006)Article Outline: The Department of Urology of the Charité Hospital, Berlin, has reported its experience in laparoscopic radical prostatectomy: 1000 patients operated on by eight surgeons over a period of almost 6 yr [1].
read more
|
The Human PC346 Xenograft and Cell Line Panel: A Model System for Prostate Cancer Progression
Wednesday, 08 February 2006
Objective: Prostate cancer (PC) model systems that reflect the different disease stages are essential for studying the development and progression of PC and for testing new treatment modalities. This review summarizes the establishment and characterization of the PC346 progression model and compares it to other available human PC cell lines and xenografts.
read more
|
European Urology - Intrafascial nerve-sparing Laproscopic Radical Prostatectomy: Do we really preserve relevant nerve-fibres?
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 955-957 (June 2006) Regardless of the technique, radical prostatectomy aims at complete excision of the carcinoma with preservation of continence and potency [1].
read more
|
European Urology - Mitogen-Activated Protein Kinase Signaling is Activated in Prostate Tumors but not Mediated by B-RAF Mutations
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1102-1110 (November 2006) Abstract - Objectives: A dysregulated mitogen-activated protein kinase (MAPK) pathway plays an important role in various malignancies and is often mediated by mutations in several oncogenes (eg, RAF, RAS).
read more
|
Substaging Pathologically Organ Confined (pT2) Prostate Cancer: An Exercise in Futility?
Wednesday, 08 February 2006
Volume 49, Issue 2, Pages 209-211 (February 2006) The anatomical extent of a malignant tumour at the different stages of its development is represented by the staging system.The anatomical extent of a malignant tumour at the different stages of its development is represented by the staging system.
read more
|
European Urology - The Importance of Cyclooxygenase in Carcinogenesis: Is It a Therapeutic Target?
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 23-25 (July 2006)
Cyclooxygenase (COX) is a key enzyme in the prostanoid biosynthetic pathway, and COX-2, the inducible isoform of cyclooxygenase, is overexpressed in various cancers.
read more
|
European Urology - The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 873-878 Article Outline: Geoffrey Chisholm was a far-sighted urologist and his innovation and forward-thinking is exemplified in this seminal paper.
read more
|
The Difficult Case in Prostate Cancer Diagnosis—When is a “Diagnostic TURP” Indicated?
Saturday, 06 May 2006
The technique of transrectal ultrasound-guided core biopsy of the prostate has been improving gradually. It is a well-known fact since the late 1980s, when the “sextant biopsy” with parasagittal sampling became “gold standard,” that aggressive prostate cancer may well be present despite negative findings on digital rectal examination and ultrasonography.
read more
|
PSA Velocity and Prostate Cancer Detection: The Absence of Evidence is not the Evidence of Absence
Wednesday, 01 March 2006
The article by Schröder et al. [1] touches on an important topic and shows evidence that adds to the current confusion about the role of prostatespecific antigen velocity (PSAV) in prostate cancer early detection and screening: in a prescreened population for prostate cancer (second round) once the serum (total) PSA has reached the cut-off value of 4 ng/ml, the PSAV adds no new information about the presence of a cancer. This is disappointing, considering the urgent need to improve the discriminative power of serum total PSA to separate subjects with prostate cancer from those without.
read more
|
European Urology - Frozen Sections for Positive Margins?
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 950-951 (June 2006) Radical prostatectomy, or probably more accurately termed total prostatectomy, is one of the most common approaches for the treatment of clinically, organ-confined prostate cancer.
read more
|
Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasentan Influence Quality of Life?
Saturday, 06 May 2006
Objective: Progression of hormone-refractory prostate cancer (HRPC) is associated with skeletal complications and bone pain, which contribute to deterioration in quality of life (QOL). The effects of new HRPC therapies on patients’ QOL need to be studied. Patient-based assessments that help quantify the risk-benefit profile of HRPC therapies are warranted. This review summarizes the known QOL literature and estimates the potential effect of atrasentan, a novel, selective endothelin A receptor antagonist (SERA), on the QOL of HRPC patients.
read more
|
European Urology - Intraoperative Frozen Section Analysis to Monitor Nerve-Sparing Radical Prostatectomy
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 948-949 (June 2006) Nerve-sparing radical prostatectomy (RPE) represents a standard surgical treatment for clinically localized prostate cancer (PCA).
read more
|
European Urology - Needle Core Length is a Quality Indicator of Systematic Transperineal Prostate Biopsy
Wednesday, 19 July 2006
Volume 50, Issue 2, Pages 266-271 (August 2006) 1. Introduction:The length of cores sampled during prostate biopsy is a parameter that can affect prostate cancer detection rate [1], [2]. The biopsies provided by the urologists should be of adequate length and quality.
read more
|
European Urology - Single-Dose Antibiotic Prophylaxis in Core Prostate Biopsy: Impact of Timing and Identification of Risk Factors
Friday, 29 September 2006
Volume 50, Issue 4, Pages 832-837 (October 2006) 1. Introduction Transrectal ultrasound-guided core prostate biopsy is a key event in the diagnosis of prostate cancer [1].
read more
|
European Urology - Testosterone and Prostate Health: Debunking Myths Demands Evidence, Caution, and Good Clinical Judgment
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 895-897 (November 2006) Article Outline: The review article by Dr Morgentaler [1] on this highly controversial topic is a timely and well-thought-out challenge to urologists worldwide.
read more
|
European Urology - Prostatic Fascial Anatomy and Positive Surgical Margins in Laparoscopic Radical Prostatectomy
Monday, 11 December 2006
Volume 51, Issue 3, Pages 598-600 (March 2007)
The magnification obtained with laparoscopy has allowed urologists to rediscover prostatic anatomy. The distinction between intrafascial, interfascial, and extrafascial dissection can be made only with the increased visual capability that is obtained with the laparoscopic approach.
read more
|
Development and Internal Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading Between Biopsy and Radical Prostatectomy Pathology
Saturday, 06 May 2006
Objective: Previous reports indicate that as many as 43% of men with low grade PCa at biopsy will be diagnosed with high-grade PCa at RP. We explored the rate of upgrading from biopsy to RP specimen in our contemporary cohort, and developed a model capable of predicting the probability of biopsy Gleason sum upgrading.
read more
|
Extended 12-Core Prostate Biopsy Increases Both the Detection of Prostate Cancer and the Accuracy of Gleason Score
Monday, 02 January 2006
Objective: To evaluate the effect of extended 12-core prostate biopsy in improving the detection rate of prostate cancer and increasing the accuracy of Gleason score.
read more
|
European Urology - Watching the Face of Janus – Active Surveillance as a Strategy to Reduce Overtreatment for Localised Prostate Cancer
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 410-412 (September 2006) Prostate cancer is a disease with the two faces of Janus: having one benevolent face of small, indolent tumours, abundant among middle-aged and elderly men, it also has the grim face of a great killer, being the second most common cancer-related cause of death within the European Union and in the United States [1], [2].
read more
|
European Urology - Rebuttal from Authors re: Urs E. Studer, Laurence Collette. Morbidity from Pelvic Lymphadenectomy in Men Undergoing Radical Prostatectomy. Eur Urol 2006;50:887–9.
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 889-892 (November 2006) Article Outline: The extent of pelvic lymphadenectomy in men with clinically localized prostate cancer represents an area of controversy.
read more
|
European Urology - Morbidity from Pelvic Lymphadenectomy in Men Undergoing Radical Prostatectomy
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 887-889 (November 2006) Article Outline: As is true for the surgical treatment of many other cancers, there is an increasing interest in determining the value of a meticulous pelvic lymph node dissection in prostate cancer patients undergoing radical prostatectomy.
read more
|
European Urology - Tumour Features in the Control and Screening Arm of A Randomized Trial of Prostate Cancer
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 70-75 (July 2006)
Abstract -
Objective:
To compare tumour characteristics at the time of diagnosis of cancers detected in the screening and control arm at the Rotterdam section of the European Randomized study of Screening for Prostate Cancer.
read more
|
Magnitude of Early Castration-Induced Primary Tumour Regression in Prostate Cancer Does Not Predict
Monday, 03 April 2006
Introduction: This study was designed to test whether early castration-induced short-term cellular changes in primary prostate tumours could predict clinical outcome in advanced disease.
read more
|
The 2002 AJCC pT2 Substages Confer No Prognostic Information on the Rate of Biochemical Recurrence After Radical Prostatectomy
Wednesday, 01 February 2006
Introduction: We examined the prognostic value of AJCC pT2 substages in prediction of biochemical recurrence (BCR) after radical prostatectomy (RP), in European patients.
read more
|
European Urology - Impact of Race, Age, Income, and Residence on Prostate Cancer Knowledge, Screening Behavior, and Health Maintenance in Siblings of Patients with Prostate Cancer
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 64-69 (July 2006) Abstract - Objective: This study evaluates self-reported changes in knowledge of prostate cancer (CaP), CaP screening behavior and other health-related activities in men whose brothers have been diagnosed with prostate cancer and to characterize those demographic subgroups of siblings at particular risk of failure to change their behavior.
read more
|
Pre-Treatment Nomogram for Disease-Specific Survival of Patients with Chemotherapy-Naive Androgen Independent Prostate Cancer
Monday, 03 April 2006
Objective: Our objective was to develop a nomogram that predicts the probability of cancer-specific survival in men with untreated androgen-independent prostate cancer (AIPC).
read more
|
Laparoscopic Sentinel Lymph Node Dissection – A Novel Technique for the Staging of Prostate Cancer
Wednesday, 01 February 2006
Objectives: Pelvic lymph node metastases indicate a poor prognosis for prostate cancer patients. The aim of this study was to evaluate the suitability of laparoscopic radioisotope guided sentinel lymph node (SLN) dissection in staging of prostate carcinoma.
read more
|
European Urology - High Radical Prostatectomy Surgical Volume is Related to Lower Radical Prostatectomy Total Hospital Charges
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 58-63 (July 2006) 1. Introduction:Several studies addressed the relationship between surgical volume (SV) and health indicators in an attempt to support the “practice makes perfect” hypothesis [1], [2], [3], [4], [5], [6].
read more
|
European Urology - Activation of the Thromboxane A2 Pathway in Human Prostate Cancer Correlates with Tumor Gleason Score and Pathologic Stage
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1021-1031 (November 2006) Abstract - Objective: We investigated the potential involvement of the thromboxane A2 (TXA2) pathway in human prostate cancer (PCa).
read more
|
IGF-II Serum Levels Increase Discrimination Between Benign Prostatic Hyperplasia and Prostate Cancer and Improve the Predictive Value of PSA in Clinical Staging
Wednesday, 01 February 2006
Purpose: IGF-I serum levels have been demonstrated as being associated with prostate cancer (PCa) and can serve as a predictive factor for the risk of PCa development. However, the role of IGF-II in PCa and its importance as a predictive marker is still unclear. Our aim was to determine PSA and IGF-II serum levels in patients with PCa and benign prostatic hyperplasia (BPH) and to analyse the value of IGF-II as an additional predictive factor in the diagnostics of PCa.
read more
|
Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer
Monday, 02 January 2006
Objective: In a cross-sectional, retrospective, non-randomised study to investigate the possibility that some patients treated with luteinizing hormone releasing hormone analogues (LHRH analogues) fail to reach castration levels of serum testosterone.
read more
|
European Urology - A (-5, -7) ProPSA Based Artificial Neural Network to Detect Prostate Cancer
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1014-1020 (November 2006) Abstract - Objective: The pro-forms of prostate specific antigen (-2,-5,-7 proPSA) and also %free PSA based artificial neural networks (ANN) have been suggested to enhance the discrimination between prostate cancer (PCa) and no evidence of malignancy (NEM).
read more
|
European Urology - Can pT0 Stage of Prostate Cancer be Predicted before Radical Prostatectomy?
Thursday, 23 November 2006
Volume 50, Issue 6, Pages Pages 1248-1253 (December 2006) Abstract - Objectives:To report our experience with biopsy-proven pT0 prostate cancer over the last 10 yr.
read more
|
Does PSA Velocity Predict Prostate Cancer in Pre-Screened Populations?
Wednesday, 01 March 2006
PSA-driven screening has been applied to a large part of the male population in many countries. An elevated PSA in secondary screens may indicate benign enlargement of the prostate rather than prostate cancer. In such cases the yearly rate of increase of PSA (PSA velocity [PSAV]) may improve the test characteristics of PSA
read more
|
Pre-operative Percent Free PSA Predicts Clinical Outcomes in Patients Treated with Radical Prostatectomy with Total PSA Levels below 10ng/ml?
Wednesday, 01 February 2006
Introduction: To evaluate the association of total prostate specific antigen (T-PSA) and percent free PSA (%F-PSA) with prostate cancer outcomes in patients treated with radical prostatectomy (RP).
read more
|
European Urology - High Incidence of Prostate Cancer Detected by Saturation Biopsy after Previous Negative Biopsy Series
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 498-505 (September 2006)
Abstract -
Objectives:
We explored the yield of saturation biopsy and developed a nomogram predicting the probability of prostate cancer (PCa) on the basis of saturation biopsy.
read more
|
European Urology - Complications and Other Surgical Outcomes Associated with Extended Pelvic Lymphadenectomy in Men with Localized Prostate Cancer
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1006-1013 (November 2006) 1. Introduction - Pelvic lymph node dissection (PLND), or pelvic lymphadenectomy, represents the most accurate staging procedure for presence of lymph node invasion (LNI) in clinically localized prostate cancer [1].
read more
|
European Urology - A Pelvic Drain Can Often Be Avoided After Radical Retropubic Prostatectomy—An Update in 552 Cases
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1241-1247 (December 2006) Abstract - Objectives: The routine placement of a pelvic drain following radical retropubic prostatectomy (RRP) may not be required.
read more
|
Natural History and Treatment of Bone Complications in Prostate Cancer
Wednesday, 01 March 2006
Bone metastases are highly prevalent in patients with prostate cancer, and they commonly present a therapeutic challenge. The natural history of prostatic bone metastases is characterized by skeletal morbidity, often producing distressing symptoms for individual patients and reducing patient autonomy and mobility. These bone metastases are usually radiologically osteoblastic, but there is also a strong osteolytic component as evidenced by marked increases in bone resorption markers. Malignant bone lesions can reduce the structural integrity of the skeleton, resulting in skeletal complications such as pathologic fracture, spinal cord compression, and severe bone pain, which adversely affect quality of life.
read more
|
European Urology - Evaluation of Color Doppler in Guiding Prostate Biopsy after HIFU Ablation
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 490-497 (September 2006)
Abstract -
Objective:
Transrectal ultrasound cannot accurately depict early cancer recurrences after prostate high-intensity focused ultrasound (HIFU) ablation. We evaluated transrectal color Doppler (CD) in guiding post-HIFU prostate biopsy.
read more
|
European Urology - Extent of Prostate-Specific Antigen Contamination in the Spanish Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1234-1240 (December 2006) Abstract - Objectives:The performance of tests outside prostate cancer screening trials (PSA contamination) may affect their statistical power.
read more
|
2005 Update on Pathology of Prostate Biopsies with Cancer?
Wednesday, 01 March 2006
Objective: To review the diagnostic and prognostic importance of pathologic findings in prostate biopsies.
read more
|
European Urology - Computerized Three-Dimensional Localization of Prostate Cancer Using Contrast-Enhanced Power Doppler and Clustering Analysis
Thursday, 21 September 2006
Volume 50, Issue 4, Pages 762-769 (October 2006) Abstract -
Objective:
To evaluate the potential benefit of semiautomated localization of prostate cancer using clustering analysis on three-dimensional (3-D) contrast-enhanced power Doppler images.
read more
|
European Urology - Duration of Testosterone Suppression after a 9.45mg Implant of the GnRH-Analogue Buserelin in Patients with Localised Carcinoma of the Prostate: A 12-Month Follow-up Study
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 483-489 (September 2006)
Abstract -
Objectives:
(1) To determine the duration of androgen deprivation after a single buserelin implant 9.45mg in the neoadjuvant setting in combination with curative radiation therapy of carcinoma of the prostate, and (2) to evaluate the time to recovery of gonadal function, and the incidence and duration of hypogonadal symptoms.
read more
|
European Urology - A Correlation of FTIR Spectra Derived from Prostate Cancer Biopsies with Gleason Grade and Tumour Stage
Thursday, 21 September 2006
Volume 50, Issue 4, Pages 750-761 (October 2006) Abstract -
Objectives:
We introduce biochemistry as a second dimension to Gleason grading, using Fourier transform infrared (FTIR) microspectroscopy. For the first time, we correlate FTIR spectra derived from prostate cancer (pCA) tissue with Gleason score and the clinical stage of the tumour at time of biopsy.
read more
|
